Tcr2 Therapeutics - TCRR STOCK NEWS

TCR² Therapeutics Inc. (Nasdaq: TCRR) announced the appointment of Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer. Dr. Harrison, who has nearly 20 years of experience in strategic planning and business development, will focus on commercial strategy and operational planning. This appointment comes as TCR² prepares for pivotal clinical trials for its lead program gavo-cel and TC-510 in 2022. Dr. Harrison's expertise includes her role in the $2.22 billion acquisition of Trillium Therapeutics by Pfizer.

TCR2 Therapeutics Inc. (TCRR), a clinical-stage cell therapy company, announced its strategic priorities for 2022. The Safety Review Team identified a recommended Phase 2 dose for gavo-cel at 1x10⁸ cells/m², with trial initiation expected in 1H 2022. Initial results from the TC-510 trial are anticipated in 2H 2022. The company aims to evaluate gavo-cel's efficacy against mesothelin-positive tumors, and plans updates on preclinical and enhanced TRuC-T cell data throughout the year. TCR2 ended Q3 2021 with $295.7 million in cash, expected to support operations into 2024.

TCR2 Therapeutics (Nasdaq: TCRR), a clinical-stage cell therapy company, announced that Garry Menzel, President and CEO, will present a company progress update at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 7:30 AM E.T. The presentation will be hosted virtually, and a live webcast can be accessed through the company's Investors page. An archived replay will be available for 30 days post-event, showcasing the company's advancements in novel T cell therapies targeting solid tumors.

TCR² Therapeutics (Nasdaq: TCRR), a clinical-stage cell therapy company, announced that CEO Garry Menzel will present an update on the company's progress at the H.C. Wainwright BioConnect Conference on January 10, 2022, at 7:00 AM ET. The presentation will take place on a virtual platform, and a live webcast will be available on the company's Investors page. An archived replay will be accessible for at least 30 days following the event. TCR² focuses on developing novel T cell therapies for cancer patients targeting solid tumors.

TCR2 Therapeutics and Arbor Biotechnologies have entered a strategic research collaboration to develop allogeneic TRuC-T cell therapies for cancer. This partnership utilizes Arbor's CRISPR gene-editing technology alongside TCR2's pioneering TRuC platform, which shows promise in treating difficult-to-address solid tumors. Arbor will receive an upfront cash payment and milestone payments for successful development phases. TCR2 aims to accelerate patient access and reduce manufacturing costs while advancing therapies for solid tumor patients.

TCR2 Therapeutics (Nasdaq: TCRR) reported Q3 2021 financial results, revealing a net loss of $26.2 million, an increase from $16.9 million in Q3 2020. Cash reserves rose to $295.7 million, supporting operations through 2023. The Phase 1 gavo-cel trial showed promising results with 15 of 16 patients experiencing tumor regression. TCR2 is collaborating with Bristol Myers Squibb to combine gavo-cel with Opdivo and Yervoy in a Phase 2 trial. R&D expenses increased to $20.3 million due to higher headcount. The company anticipates identifying the recommended Phase 2 dose by year-end.

TCR2 Therapeutics Inc. (Nasdaq: TCRR) announced the expansion of its manufacturing capacity by securing a second clean room at ElevateBio BaseCamp. This move aims to enhance cGMP capacity for upcoming clinical trials, including a Phase 2 trial for gavo-cel targeting mesothelin-expressing solid tumors and a Phase 1 trial for TC-510. The company will shift manufacturing operations from the CGT Catapult in the UK to focus on its Rockville, MD, facility. The strategy is expected to optimize efficiencies and simplify regulatory pathways for its cell therapy products.

TCR² Therapeutics (TCRR) announced a collaboration with Bristol Myers Squibb to evaluate gavo-cel in a Phase 2 trial for treatment-refractory mesothelin-expressing solid tumors. This trial will assess gavo-cel's efficacy combined with Opdivo® and Yervoy® in patient cohorts with non-small cell lung cancer, ovarian cancer, malignant pleural mesothelioma, and cholangiocarcinoma. The trial aims to characterize gavo-cel's antitumor activity and safety, emphasizing its potential synergy with immune checkpoint inhibitors.

TCR2 Therapeutics Inc. (Nasdaq: TCRR) provided key updates on its clinical-stage cell therapy pipeline during its R&D Day. Highlights include the completion of a 3-patient cohort for gavo-cel with promising safety results and an expected recommendation for the Phase 2 dose by year-end. The company deprioritized TC-110, focusing on solid tumors with new candidates TC-510 and TC-520. Additionally, TCR2 plans to expand into autoimmune diseases and anticipates lead candidates in 2022 for allogeneic programs and TRuC Tregs targeting Graft versus Host Disease.